Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $5.6 million.

  • Cytek Biosciences' Share-based Compensation fell 2006.24% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year increase of 214.39%. This contributed to the annual value of $26.8 million for FY2024, which is 2177.07% up from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' Share-based Compensation is $5.6 million, which was down 2006.24% from $6.8 million recorded in Q2 2025.
  • Cytek Biosciences' Share-based Compensation's 5-year high stood at $7.2 million during Q2 2024, with a 5-year trough of $456000.0 in Q1 2021.
  • For the 5-year period, Cytek Biosciences' Share-based Compensation averaged around $4.8 million, with its median value being $5.6 million (2025).
  • As far as peak fluctuations go, Cytek Biosciences' Share-based Compensation surged by 184841.27% in 2021, and later crashed by 2006.24% in 2025.
  • Cytek Biosciences' Share-based Compensation (Quarter) stood at $3.0 million in 2021, then soared by 48.44% to $4.5 million in 2022, then grew by 26.97% to $5.7 million in 2023, then rose by 23.53% to $7.0 million in 2024, then dropped by 19.49% to $5.6 million in 2025.
  • Its Share-based Compensation was $5.6 million in Q3 2025, compared to $6.8 million in Q2 2025 and $6.6 million in Q1 2025.